Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,158 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Progression Clear all
Not yet recruiting Phase 2 Interventional

Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo

NCT07683026
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Golimumab, Placebo (matching golimumab)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years to 44 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 25, 2026, 2:57 PM EDT
Completed Phase 2 Interventional Results available

Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma

NCT01954745
View directory record Official record
Conditions
Bile Duct Cancer, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct
Interventions
Cabozantinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 25, 2026, 2:57 PM EDT
Completed Phase 2 Interventional Results available

Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas

NCT00076102
View directory record Official record
Conditions
Neurofibromatosis 1, Neurofibroma, Plexiform
Interventions
Pirfenidone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 25, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma

NCT01621672
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Revlimid
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 25, 2026, 2:57 PM EDT
Withdrawn No phase listed Observational

Study to Evaluate Bacterial Activity That Drives the Progression of Clinical Infection

NCT03854695
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 25, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

NCT03061812
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Rovalpituzumab tesirine, Topotecan, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
31
States / cities
Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 25, 2026, 2:57 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Equity in Prevention and Progression of Hypertension by Addressing Barriers to Nutrition and Physical activitY

NCT05367544
View directory record Official record
Conditions
Prehypertension, Hypertension, Blood Pressure
Interventions
Health Education, Individual-Level Peer Support, Community-Level Peer Support
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
416 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 2:57 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

NCT05169567
View directory record Official record
Conditions
Breast Neoplasm, Neoplasm Metastasis
Interventions
Abemaciclib, Fulvestrant, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
60
States / cities
Phoenix, Arizona • Springdale, Arkansas • Fullerton, California + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 2:57 PM EDT
Completed No phase listed Observational

Uric Acid and Long-term Outcomes in Chronic Kidney Disease

NCT01158911
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2010 · Synced Oct 25, 2026, 2:57 PM EDT
Completed Phase 2 Interventional Results available

Respiratory Syncytial Virus - RSV Protocol

NCT01502072
View directory record Official record
Conditions
Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Pneumonia, Cancer, Acute Leukemia
Interventions
Ribavirin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 25, 2026, 2:57 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Impact of Diabetes on Left Ventricular Remodeling

NCT01052272
View directory record Official record
Conditions
Diabetes
Interventions
Ramipril, Candesartan cilexetil, Allopurinol
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 25, 2026, 2:57 PM EDT
Completed Phase 2 Interventional

Vitamin D to Slow Progression of Knee Osteoarthritis

NCT00306774
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Vitamin D (cholecalciferol), Placebo
Dietary Supplement
Lead sponsor
Tufts Medical Center
Other
Eligibility
45 Years to 90 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2011 · Synced Oct 25, 2026, 2:57 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

NCT03164616
View directory record Official record
Conditions
Non Small Cell Lung Cancer NSCLC
Interventions
Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
16
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 25, 2026, 2:57 PM EDT
Completed No phase listed Observational

A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)

NCT02322255
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Not listed
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
Up to 65 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 25, 2026, 2:57 PM EDT
Terminated Phase 2 Interventional Results available

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

NCT02949843
View directory record Official record
Conditions
EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab, Targeted Molecular Therapy, Tyrosine Kinase Inhibitor
Drug · Biological · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 25, 2026, 2:57 PM EDT
Not yet recruiting Phase 2 Interventional

MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

NCT07029776
View directory record Official record
Conditions
Multiple Myeloma (MM)
Interventions
teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy
Drug · Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 25, 2026, 2:57 PM EDT
Terminated No phase listed Observational

Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer

NCT03290508
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prolaris Testing
Diagnostic Test
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
65 Years and older · Male only
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
34
States / cities
Homewood, Alabama • Mesa, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 25, 2026, 2:57 PM EDT
Terminated Phase 4 Interventional Results available

A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?

NCT02287025
View directory record Official record
Conditions
Physician Education
Interventions
Regorafenib (Stivarga, BAY73-4506), iPAD application, Bayer specialist
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Anniston, Alabama • Anaheim, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 25, 2026, 2:57 PM EDT
Recruiting No phase listed Observational

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

NCT02269592
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, Hematological Malignancies, B-cell Malignancy, Low-grade, Myelodysplastic Syndrome With Low-grade Lesions, IgG Monoclonal Gammopathy of Uncertain Significance, Smoldering Multiple Myeloma, Waldenstrom Macroglobulinemia
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
7
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 25, 2026, 2:57 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

The Efficacy of Systemic Valacyclovir (Valtrex) on Periodontitis

NCT05712343
View directory record Official record
Conditions
Severe Periodontitis
Interventions
Valacyclovir group, Control group
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 25, 2026, 2:57 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer

NCT04467515
View directory record Official record
Conditions
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
Interventions
CAM-H2
Drug
Lead sponsor
Precirix
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Duarte, California • Stanford, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 25, 2026, 2:57 PM EDT
Withdrawn Phase 1 Interventional

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

NCT05375825
View directory record Official record
Conditions
Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe), Epithelial Tumors, Malignant, Pleural Effusions, Malignant, Mesothelin (Msln)
Interventions
Cytoreductive surgery, LMB-100, Immunohistochemical Assay for Mesothelin
Procedure · Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 25, 2026, 2:57 PM EDT
Completed Phase 2 Interventional Results available

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC

NCT03689855
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, NSCLC
Interventions
Ramucirumab, Atezolizumab, Peripheral blood draw, Biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 25, 2026, 2:57 PM EDT